Hypercholesterolaemia
Conditions
Brief summary
Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.
Interventions
Alirocumab 300 mg injection
Sponsors
Federico II University
Study design
Observational model
CASE_ONLY
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
\- Patients under alirocumab 300mg treatment.
Exclusion criteria
* Age \< 18 years o \> 80 years; * Patients who refuse to participate and to sign informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Description of adherence of treatment with alirocumab 300mg in a real-life Italian population. | 6-12-24-36 months | Adherence will be assessed in terms of Medical Possession Ratio (MPR) which is defined as the ratio between the treatment units dispensed during the treatment period and the duration of the treatment period itself. |
| Description of persistence of treatment with alirocumab 300mg in a real-life Italian population. | 6-12-24-36 months | Persistence will be assessed in terms of therapeutic continuity from the start of treatment to enrollment. |
| Description of efficacy of treatment with alirocumab 300mg in a real-life Italian population. | 6-12-24-36 months | Efficacy of treatment will be evaluated as a change in the LDL (deltaLDL) value from the start of treatment (percentage and absolute value). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Description of safety of treatment with alirocumab 300mg in a real-life Italian population. | 6-12-24-36 months | Safety will be evaluated in terms of adverse reactions or intolerance to the drug. |
Countries
Italy
Contacts
CONTACTPasquale Perrone Filardi
Outcome results
None listed